Intravitreal pegaptanib as adjunctive treatment for stage 3+ ROP shown to be effective in a prospective, randomized, controlled multicenter clinical trial

European Journal of Ophthalmology

Volumn 22, Issue 5, 2012, Pages 685-686

  Mintz Hittner, Helen A ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Bevacizumab; Pegaptanib; Retinopathy of Prematurity; Stage 3+ or APROP

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; VASCULOTROPIN ANTIBODY;

ADJUVANT THERAPY; ARTICLE; CONTROLLED STUDY; DIODE LASER; DRUG EFFICACY; FOLLOW UP; HUMAN; INFANT; LASER SURGERY; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RETROLENTAL FIBROPLASIA;

ANGIOGENESIS INHIBITORS; APTAMERS, NUCLEOTIDE; COMBINED MODALITY THERAPY; HUMANS; INFANT, NEWBORN; INTRAVITREAL INJECTIONS; LASER COAGULATION; LASERS, SEMICONDUCTOR; PROSPECTIVE STUDIES; RETINOPATHY OF PREMATURITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84864942336     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/ejo.5000176     Document Type: Article

References (5)

1. Autrata R, Kejcirova I, Senkova K, Holousova M, Dolezel Z, Borek I. Efficacy of intravitreal pegaptanib as adjunctive treatment for stage 3+ retinopathy of prematurity in zone I and posterior zone II. Eur J Ophthalmol 2012; 22.
2. Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011; 364: 603-15.
3. Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R. Reactivation of retinopathy of prematurity after bevacizumab Injection. Arch Ophthalmol Epub 2012 Apr 9.
4. Hartnett ME. Studies on the pathogenesis of avascular retina and neovascularization into the vitreous in peripheral severe retinopathy of prematurity (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2010; 108: 96-119.
5. Sato T, Wada K, Arahori H, et al. Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 2012; 153: 327-33.